Ragweed-SPIRE Follow-On Study

N/ACompletedNCT02396680

Circassia Limited249 enrolled

Overview

The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.

Study Type

OBSERVATIONAL

Enrollment

249

Conditions

Rhinoconjunctivitis Ragweed Allergy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: ° Previously randomised into and completed at least 6 of 8 treatment visits in Study TR006 Exclusion Criteria: * Subject or Investigator have been informed of treatment received in Study TR006 * Subjects with significant allergy to animal dander * Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies * History of recurrent acute sinusitis or chronic sinusitis * Received treatment with an investigational drug within 4 weeks of Screening * Unable to understand study requirements or unable to communicate clearly with Investigator

Locations (3)

Kanata Allergy Services

Kanata, Ontario, Canada

Inflamax Research

Mississauga, Ontario, Canada

Windsor Allergy Asthma Associates

Windsor, Ontario, Canada